Trials / Completed
CompletedNCT00174863
Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
Evaluation of Two Doses of SR31747A (75 mg and 125 mg) in Non-Metastatic Androgen-Independent Prostate Cancer. Randomized, Double-Blind, Placebo Controlled Phase II Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 232 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of SR31747 given at 75 or 125mg per day versus placebo in androgen prostate cancer patient without distant metastases with Time to Clinical progression as main objective and PSA parameters, Tumor response, survival , safety,Tumor-related symptoms deterioration Quality of Life, PK analysis as secondary objectives
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SR31747A |
Timeline
- Start date
- 2003-10-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2005-09-15
- Last updated
- 2008-12-23
Locations
13 sites across 13 countries: Australia, Belgium, Canada, Chile, Czechia, France, Italy, Mexico, Netherlands, Poland, Portugal, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00174863. Inclusion in this directory is not an endorsement.